SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

DexCom, Inc. – ‘8-K’ for 8/1/22

On:  Friday, 8/5/22, at 4:52pm ET   ·   For:  8/1/22   ·   Accession #:  1093557-22-151   ·   File #:  0-51222

Previous ‘8-K’:  ‘8-K’ on 7/28/22 for 7/26/22   ·   Next:  ‘8-K’ on 8/31/22 for 8/25/22   ·   Latest:  ‘8-K’ on 2/15/24 for 2/13/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/05/22  DexCom, Inc.                      8-K:8       8/01/22   10:365K

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     34K 
 5: R1          Cover Page                                          HTML     46K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- dxcm-20220801_htm                   XML     21K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- dxcm-20220801_lab                     XML     67K 
 4: EX-101.PRE  XBRL Presentations -- dxcm-20220801_pre              XML     33K 
 2: EX-101.SCH  XBRL Schema -- dxcm-20220801                         XSD      9K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    16K 
10: ZIP         XBRL Zipped Folder -- 0001093557-22-000151-xbrl      Zip    107K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  dxcm-20220801  
 i false i 000109355700010935572022-08-012022-08-01

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM  i 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):  i August 1, 2022
dxcm-20220801_g1.jpg
 i DEXCOM, INC.
(Exact Name of the Registrant as Specified in Its Charter)

 i Delaware i 000-51222 i 33-0857544
(State or Other Jurisdiction of Incorporation or Organization)(Commission File Number)(I.R.S. Employer Identification No.)
 i 6340 Sequence Drive,  i San Diego,  i CA  i 92121
(Address of Principal Executive Offices, Including Zip Code)
( i 858)  i 200-0200
(Registrant’s Telephone Number, Including Area Code)
(Former Name, Former Address, and Former Fiscal Year, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 i Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
 i Common Stock, $0.001 Par Value Per Share i DXCM i Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 




ITEM 8.01.
OTHER EVENTS.
On August 1, 2022, DexCom, Inc. (the “Company”) entered into an accelerated share repurchase agreement (“ASR”) with JPMorgan Chase Bank, National Association (“JPMorgan”) to repurchase shares of its common stock, par value $0.001 per share (“Common Stock”) in an aggregate notional amount of up to $700.0 million. Under the ASR, the Company made an initial payment to JPMorgan of $700.0 million, and received an initial delivery of approximately 3.0 million shares of its Common Stock on August 3, 2022. The final number of shares to be repurchased and the final aggregate notional amount will be based on the daily average volume-weighted average price of the Company’s Common Stock during the term of the ASR, and in the case of the final number of shares, less a discount. The final settlement of the ASR is expected to occur during the third quarter of 2022.
The ASR transaction will be effectuated pursuant to the Company’s previously announced $700.0 million share repurchase program, with a repurchase period ending no later than June 30, 2023.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DEXCOM, INC.
By: 
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
Date:


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
6/30/23None on these Dates
Filed on:8/5/22
8/3/22
For Period end:8/1/22
 List all Filings 
Top
Filing Submission 0001093557-22-000151   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 10:20:08.1am ET